Phaseline

Companies › Oneness Biotech

Oneness Biotech: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 3 Phase 2, 1 Phase 1; Metabolic and endocrine, Immunology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
FB825–Phase 2Atopic Dermatitis; Allergic AsthmaMay 2027
Xianglei Tangzu Gao
Herbal preparation containing extracts of Plectranthus amboinicus and Centella asiatica
–Phase 2Diabetic Foot Ulcer–
SNS851
siRNA treatment targeting metabolic diseases
–Phase 1Metabolic Disease–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06531512Xianglei Tangzu GaoPhase 2Diabetic Foot UlcerMetabolic and endocrineMay 2026
NCT07417124SNS851Phase 1Metabolic DiseaseMetabolic and endocrineOct 2026
NCT06397911FB825Phase 2Atopic DermatitisImmunologyMay 2027
NCT05008965FB825Phase 2Allergic AsthmaImmunologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Rare Thyroid Therapeutics International Eddingpharm (Zhuhai) Ribotek Biopharmaceuticals (Shandong) Amorphical Alveus Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.